Gateway Drug Theory

Gateway Drug Theory proposes that exposure to a mild experience lowers the threshold for progressively more intense versions of that experience. In its original context, the theory suggests mild substances lead to harder ones. As a business mental model, the mechanism is more broadly useful: small initial commitments create the conditions for larger ones. A free trial leads to a paid subscription. A low-cost product leads to the premium tier. A simple onboarding experience leads to deep platform dependency. The mechanism operates through two channels — habituation (the mild experience normalises the category) and infrastructure (the initial commitment creates switching costs, relationships, and workflows that make escalation natural). Smart founders design gateway experiences deliberately; naive ones stumble into them accidentally.

Design your entry product as a deliberate gateway — not just cheap, but architected to create the habits, dependencies, and data that make upgrading natural. Measure not just initial conversion but the progression rate from entry to core product. The health of your gateway is measured by what percentage of users move deeper, not just how many enter.

Gateway Drug Theory describes how small initial exposures create conditions for progressively deeper engagement. In business, it operates through product ladders, freemium models, and ecosystem design. The strategic skill is designing entry experiences that naturally create demand for the next level.